InterMune PT Raised to $23.00 at Stifel Nicolaus (ITMN)
Stifel Nicolaus hoisted their target price on shares of InterMune (NASDAQ:ITMN) from $20.00 to $23.00 in a research note issued on Friday, American Banking News.com reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 38.81% from the stock’s previous close.
The analysts wrote, “We’ve adjusted our model to include peak U.S. Esbriet sales of approximately $900M – an estimate that is based on some fairly conservative pricing ($65K/year at launch) and peak penetration (20-25%) estimates,” the report noted. “We continue to assign a high probability of success to a positive ASCEND outcome but still view P3 nintedanib data as a bit of a wildcard limiting visibility into our model (we don’t think being potentially relegated to a second-line therapy is good thing in an indication where disease progression remains poorly defined). Our FY14/forward-year Esbriet estimates have decreased marginally.”
Other equities research analysts have also recently issued reports about the stock. Analysts at UBS AG raised their price target on shares of InterMune from $15.00 to $19.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of InterMune in a research note to investors on Friday, November 1st. They now have a $17.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of InterMune from $16.00 to $17.00 in a research note to investors on Thursday, October 31st. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. InterMune has an average rating of “Buy” and an average price target of $18.00.
InterMune (NASDAQ:ITMN) traded up 7.00% during mid-day trading on Friday, hitting $17.73. The stock had a trading volume of 1,868,490 shares. InterMune has a 1-year low of $8.21 and a 1-year high of $16.88. The stock’s 50-day moving average is $14.14 and its 200-day moving average is $13.83. The company’s market cap is $1.454 billion.
InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, October 30th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.10. The company had revenue of $19.72 million for the quarter, compared to the consensus estimate of $16.44 million. During the same quarter in the prior year, the company posted ($0.63) earnings per share. The company’s quarterly revenue was up 161.9% on a year-over-year basis. Analysts expect that InterMune will post $-2.70 EPS for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.